{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T02:04:54Z","timestamp":1791425094373,"version":"4.3.3"},"reference-count":30,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:00:00Z","timestamp":1771027200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:00:00Z","timestamp":1771027200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hidradenitis suppurativa (HS) is a chronic, relapsing, debilitating skin disease characterized by deep\u2010seated nodules, abscesses and tunnels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To investigate the efficacy of bimekizumab using International Hidradenitis Suppurativa Severity Score System (IHS4) outcomes in patients with moderate to severe HS in the pooled BE HEARD I and II Phase 3 studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients received (initial\/maintenance) bimekizumab 320\u2009mg every 2\u2009weeks (Q2W)\/Q2W, bimekizumab Q2W\/every 4\u2009weeks (Q4W), bimekizumab Q4W\/Q4W or placebo\/bimekizumab Q2W. Change from baseline (CfB) in IHS4, IHS4 severity stages and the dichotomous IHS4\u201055\/75\/90\/100 (an improvement of at least 55%\/75%\/90%\/100% in IHS4 from baseline) are reported to Week 48. Lesion count data by lesion type are reported to Week48.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 1014 patients were enrolled across BE HEARD I and II. At baseline, mean (standard deviation [SD]) IHS4 for bimekizumab\u2010treated patients ranged from 33.4 (25.4) for bimekizumab Q2W\/Q2W to 36.0 (34.0) for bimekizumab Q2W\/Q4W versus 30.6 (21.8) for placebo. At Week16, patients receiving bimekizumab demonstrated greater reductions in mean (SD) IHS4 from baseline, ranging from \u221217.2 (24.8) for bimekizumab Q4W\/Q4W to \u221217.8 (21.1) for bimekizumab Q2W\/Q2W versus \u22126.1 (16.3) for placebo. Proportions of patients with severe HS at baseline ranged from 83.7% (bimekizumab Q2W\/Q2W) to 88.4% (bimekizumab Q2W\/Q4W) and decreased by ~50% to Week48 across all treatment arms, ranging from 28.6% (placebo\/bimekizumab Q2W) to 34.3% (bimekizumab Q2W\/Q2W). Proportions of patients with IHS4\u2009=\u20090 at Week48 ranged from 23.7% (bimekizumab Q2W\/Q4W) to 26.7% (placebo\/bimekizumab Q2W). At Week16, IHS4\u201055, IHS4\u201075, IHS4\u201090 and IHS4\u2010100 thresholds were achieved by greater proportions of patients treated with bimekizumab versus placebo, while comparable improvements were seen across treatment arms from Week16 to Week48. At Week16, lesion counts were lower for patients treated with bimekizumab versus placebo, decreasing to comparable numbers across all groups at Week48.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Bimekizumab\u2010treated patients showed improvements across IHS4 outcome measures.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jdv.70356","type":"journal-article","created":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T10:30:11Z","timestamp":1771065011000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Bimekizumab efficacy using\n                    <scp>IHS4<\/scp>\n                    outcomes in hidradenitis suppurativa: Results from\n                    <scp>BE HEARD<\/scp>\n                    I and\n                    <scp>II<\/scp>"],"prefix":"10.1111","author":[{"given":"Thrasyvoulos","family":"Tzellos","sequence":"first","affiliation":[{"name":"European Hidradenitis Suppurativa Foundation (EHSF) e.V  Dessau Germany"},{"name":"Department of Dermatology Nordland Hospital Trust  Bod\u00f8 Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos J.","family":"Giamarellos\u2010Bourboulis","sequence":"additional","affiliation":[{"name":"European Hidradenitis Suppurativa Foundation (EHSF) e.V  Dessau Germany"},{"name":"4th Department of Internal Medicine National and Kapodistrian University of Athens, Medical School  Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelsey R.","family":"van Straalen","sequence":"additional","affiliation":[{"name":"Department of Dermatology Erasmus University Medical Center  Rotterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Martorell","sequence":"additional","affiliation":[{"name":"European Hidradenitis Suppurativa Foundation (EHSF) e.V  Dessau Germany"},{"name":"Department of Dermatology Hospital de Manises  Valencia Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Kirby","sequence":"additional","affiliation":[{"name":"European Hidradenitis Suppurativa Foundation (EHSF) e.V  Dessau Germany"},{"name":"St Vincent's University Hospital, Elm Park and the Charles Institute University College Dublin  Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afsaneh","family":"Alavi","sequence":"additional","affiliation":[{"name":"European Hidradenitis Suppurativa Foundation (EHSF) e.V  Dessau Germany"},{"name":"Department of Dermatology Mayo Clinic College of Medicine and Science  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koremasa","family":"Hayama","sequence":"additional","affiliation":[{"name":"Division of Cutaneous Science, Department of Dermatology Nihon University School of Medicine  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saakshi","family":"Khattri","sequence":"additional","affiliation":[{"name":"Department of Dermatology The Mount Sinai Hospital  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne","family":"Gulliver","sequence":"additional","affiliation":[{"name":"Newlab Clinical Research Inc.  St John's Newfoundland and Labrador Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Sayed","sequence":"additional","affiliation":[{"name":"European Hidradenitis Suppurativa Foundation (EHSF) e.V  Dessau Germany"},{"name":"Department of Dermatology University of North Carolina School of Medicine  Chapel Hill North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah","family":"Davis","sequence":"additional","affiliation":[{"name":"UCB  Morrisville North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Rolleri","sequence":"additional","affiliation":[{"name":"UCB  Morrisville North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Crater","sequence":"additional","affiliation":[{"name":"UCB  Morrisville North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Pansar","sequence":"additional","affiliation":[{"name":"UCB  Brussels Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00e9my","family":"Lambert","sequence":"additional","affiliation":[{"name":"UCB  Colombes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos C.","family":"Zouboulis","sequence":"additional","affiliation":[{"name":"European Hidradenitis Suppurativa Foundation (EHSF) e.V  Dessau Germany"},{"name":"Department of Dermatology, Staedtisches Klinikum Dessau Brandenburg Medical School Theodor Fontane and Faculty of Health Sciences Brandenburg  Dessau Germany"},{"name":"Department of Venereology, Staedtisches Klinikum Dessau Brandenburg Medical School Theodor Fontane and Faculty of Health Sciences Brandenburg  Dessau Germany"},{"name":"Department of Allergology, Staedtisches Klinikum Dessau Brandenburg Medical School Theodor Fontane and Faculty of Health Sciences Brandenburg  Dessau Germany"},{"name":"Department of Immunology, Staedtisches Klinikum Dessau Brandenburg Medical School Theodor Fontane and Faculty of Health Sciences Brandenburg  Dessau Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,2,14]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.1159\/000431175"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16603"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14214"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.12.651"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15448"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20550"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504370"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1159\/000491547"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212127"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.07.010"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16147"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.1159\/000529848"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1159\/000517017"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18163"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14338"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00101-6"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15748"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19525"},{"key":"e_1_2_14_20_1","unstructured":"NCT06411379:https:\/\/clinicaltrials.gov\/study\/NCT06411379."},{"key":"e_1_2_14_21_1","unstructured":"NCT05819398:https:\/\/clinicaltrials.gov\/study\/NCT05819398."},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18632"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.1159\/000528968"},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20472"},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20369"},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.12.044"},{"key":"e_1_2_14_27_1","unstructured":"NCT04242446:https:\/\/clinicaltrials.gov\/study\/NCT04242446?term=be%20heard%20I&rank=1."},{"key":"e_1_2_14_28_1","unstructured":"NCT04242498:https:\/\/clinicaltrials.gov\/study\/NCT04242498?term=be%20heard%20II&rank=2."},{"key":"e_1_2_14_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13216"},{"key":"e_1_2_14_30_1","unstructured":"GargA KimballAB GuillemP et\u00a0al.Bimekizumab impact on hidradenitis suppurativa lesions over 2\u2009years: Data from BE HEARD EXT. Presented at EADV 2025 poster P2839."},{"key":"e_1_2_14_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14609"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.70356","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.70356","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.70356","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T10:30:14Z","timestamp":1771065014000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.70356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,14]]},"references-count":30,"alternative-id":["10.1111\/jdv.70356"],"URL":"https:\/\/doi.org\/10.1111\/jdv.70356","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,14]]},"assertion":[{"value":"2025-07-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"jdv.70356"}}